
Opinion|Videos|August 22, 2024
EHA 2024 Updated Data on BTKi Degraders as Emerging Novel Agents in R/R CLL
The panel explores potential applications and impact of BTK inhibitor degraders as an emerging class of novel agents for treating relapsed/refractory chronic lymphocytic leukemia.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Briefly share perspective/insights on emerging novel agents in R/R CLL: BTKi degraders
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
VGX-3100 Elicits Regression and Clearance in HPV-16/18–Associated Cervical HSILs
2
EVX-01 Plus Pembrolizumab Yields Neoantigen-Specific T-Cell Responses in Advanced Melanoma
3
IDP-023 Plus Isatuximab Drives Responses in Daratumumab-Refractory Multiple Myeloma
4
Canakinumab Reduces Nodule Size in High-Risk Lung Precancers
5


